drugset / Trial / NCT01431092

Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia

NCT01431092

RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this trial, researchers aim to investigate if prolonged-release melatonin can facilitate the withdrawal of chronic benzodiazepine administration in patients with schizophrenia. Furthermore, researchers will investigate the association of benzodiazepine dose reduction with the following clinically important variables: sleep, psychophysiology, cognition, social function, and quality of life.

Timeline

Start
2011-10
Primary completion
2014-06
Completion
2014-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 2 mg